17-ODYA (Synonyms: Alk-16) |
| Catalog No.GC12757 |
17-ODYA, a non-selective inhibitor of both ω-hydroxylation and epoxygenation of arachidonic acid via cytochrome P450 (IC50<100nM).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 34450-18-5
Sample solution is provided at 25 µL, 10mM.
17-ODYA, a non-selective inhibitor of both ω-hydroxylation and epoxygenation of arachidonic acid via cytochrome P450 (IC50<100nM). 17-ODYA effectively suppressed the production of 20-hydroxyeicosatetraenoic acid, epoxyeicosatrienoic acids, and dihydroxyeicosatrienoic acids by rat renal cortical microsomes when exposed to arachidonic acid[1,2].
17-ODYA as the highest unique metabolite in periapical abscesses, acts an essential role in the Pathogenesis of Periapical Abscesses, one of the most frequent pathologic lesions in the alveolar bone. 17-ODYA caused significant up-regulation of interleukin-1α, interleukin-1β, interleukin-6, matrix metalloproteinase-1, monocyte chemoattractant protein-1 and platelet-derived growth factor alpha and vascular endothelial growth factor alpha at 10μmol/L in periodontal ligament fibroblasts.1μmol/L 17-ODYA caused the same effect in peripheral blood mononuclear cells. These affected cytokines have important biological activities in coordinating the body's response to infection[3].
17-ODYA delivered via the superfusate for 45mins at 10mmol/l, inhibits both local and conducted responses of microiontophoresis of ACh evoked vasodilation that conducted along arterioles in C57Bl6 mice[4].
References:
[1] Zou A P, Ma Y H, Sui Z H, et al. Effects of 17-octadecynoic acid, a suicide-substrate inhibitor of cytochrome P450 fatty acid omega-hydroxylase, on renal function in rats[J]. Journal of Pharmacology and Experimental Therapeutics, 1994, 268(1): 474-481.
[2] Manicam C, Ginter N, Li H, et al. Compensatory vasodilator mechanisms in the ophthalmic artery of endothelial nitric oxide synthase gene knockout mice[J]. Scientific reports, 2017, 7(1): 7111.
[3] Altaie A M, Mohammad M G, Madkour M I, et al. The essential role of 17-octadecynoic acid in the pathogenesis of periapical abscesses[J]. Journal of Endodontics, 2023, 49(2): 169-177. e3.
[4] Hnngerford J E, Sessa W C, Segal S S. Vasomotor control in arterioles of the mouse cremaster muscle[J]. The FASEB journal, 2000, 14(1): 197-207.
| Cell experiment [1]: | |
|
Cell lines |
Human neutrophils |
|
Preparation Method |
Pre-warmed human neutrophil suspensions (37°C, 5 million cells/ml in HBSS containing 1.6 mM CaCl2) were incubated 5 minutes with vehicle (DMSO), PF-4708671 (30μM, 5 minutes), or 17-ODYA (30μM, 30 minutes), then treated with 1μM of LTB4 for the indicated times. Samples then were processed and analyzed for LTB4 biosynthesis, then performing kinetic experiments in which neutrophils were incubated with 1μM LTB4. |
|
Reaction Conditions |
30μM 17-ODYA for 30 minutes |
|
Applications |
17-ODYA increased LTB4 half-life by 5 folds, from ~10 sminutes to ~50 minutes. In comparison, PF-4708671 increased the half-life of LTB4 by 7.5 folds, from ~20 minutes to ~150 minutes. |
| Animal experiment [2]: | |
|
Animal models |
Male Sprague-Dawley rats (9-12 week old) |
|
Preparation Method |
Rats (n=9) were pretreated 30 mins before subarachnoid hemorrhage (SAH) with N-hydroxy-N'-(4-butyl-2-methylphenyl) formamidine (HET0016) (10mg/kg iv) or 17-ODYA (1.5nmol intrathecally) (n=7 each) or vehicle (n=15). An additional control group of rats (n=9) received an infusion of an equal volume of artificial cerebrospinal fluid in the cisterna magna SAH was induced by injecting 0.3 mL of blood into the cisterna magna over a 10-min period. The effects of two inhibitors on the changes on regional cerebral blood flow (rCBF) after induction of SAH were measured with laser-Doppler flowmetry. |
|
Dosage form |
1.5nM, 50μL, cisterna magna injection |
|
Applications |
Both 17-ODYA and HET0016 attenuated fall in rCBF recorded at 10mins after induction of SAH by 40%, and rCBF completely recovered within 60mins after induction of SAH in rats treated with 17-ODYA and within 90mins in rats treated with HET0016. |
|
References: [1] Archambault A S, Turcotte C, Martin C, et al. Leukotriene B₄ Metabolism and p70S6 Kinase 1 Inhibitors: PF-4708671 but Not LY2584702 Inhibits CYP4F3A and the ω-Oxidation of Leukotriene B₄ In Vitro and In Cellulo[J]. Plos one, 2017, 12(1): e0169804. |
|
| Cas No. | 34450-18-5 | SDF | |
| Synonyms | Alk-16 | ||
| Chemical Name | octadec-17-ynoic acid | ||
| Canonical SMILES | OC(CCCCCCCCCCCCCCCC#C)=O | ||
| Formula | C18H32O2 | M.Wt | 280.45 |
| Solubility | 1 mg/mL in DMSO, 10mg/mL in DMF,10mg/mL in ethanol | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.5657 mL | 17.8285 mL | 35.657 mL |
| 5 mM | 0.7131 mL | 3.5657 mL | 7.1314 mL |
| 10 mM | 0.3566 mL | 1.7828 mL | 3.5657 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 11 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *